SCHEMBL4184944

SCHEMBL4184944

OB(O)Oc1cccc(CBr)c1

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.38
TRPA1 O75762 1/20 0.38
ALDH1A1 P00352 1/20 0.38
MAOB P27338 2/20 0.38
CETP P11597 2/20 0.38
MEP1B Q16820 1/20 0.37
CYP4F2 P78329 2/20 0.35
CYP4A11 Q02928 2/20 0.35
BCHE P06276 1/20 0.35
HSD17B10 Q99714 1/20 0.35
IDO1 P14902 2/20 0.34
AGXT P21549 2/20 0.34
TAAR1 Q96RJ0 2/20 0.34
CALM1 P0DP23 1/20 0.33
CAMKK2 Q96RR4 1/20 0.33
MRGPRX4 Q96LA9 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1250219 0.82 ENPP2 (0.52) TSHRMAOBCYP4F2CYP4A11IDO1
SCHEMBL7582199 0.81 MAPK1 (0.44) TSHRALDH1A1
SCHEMBL29643534 0.81 ENPP2 (0.48) ALDH1A1MAOBTAAR1
SCHEMBL27569009 0.81 ENPP2 (0.48) ALDH1A1MAOBTAAR1
SCHEMBL29654293 0.80 NOS1 (0.45) TSHRALDH1A1CETPBCHEHSD17B10
SCHEMBL28111443 0.80 NOS1 (0.45) TSHRALDH1A1CETPBCHEHSD17B10
SCHEMBL27896280 0.79 CYP4F2 (0.57) ALDH1A1CYP4F2CYP4A11TAAR1
Hydrochloric Acid SCHEMBL28156681 0.79 ENPP2 (0.47) ALDH1A1MAOBIDO1AGXTTAAR1
SCHEMBL6677730 0.79 ENPP2 (0.41) TSHRALDH1A1
SCHEMBL29172589 0.78 ALOX5 (0.45) CYP4F2CYP4A11TAAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118978517-A Preparation method and application of radioactive probe targeting monoamine oxidase B 中国科学院高能物理研究所 2024-11-19 CN claimed
CN-117797651-A Preparation method and separation application of charge reversible pore-balancing membrane 浙江工业大学 2024-04-02 CN claimed
CN-117797651-A Preparation method and separation application of charge reversible pore-balancing membrane 浙江工业大学 2024-04-02 CN disclosed
WO-2023165523-A1 AROMATIC RING-SUBSTITUTED METHOXY DERIVATIVE AND USE THEREOF 上海璎黎药业有限公司 2023-09-07 WO disclosed
CN-116693514-A Aromatic ring substituted methoxy derivative and application thereof 上海璎黎药业有限公司 2023-09-05 CN disclosed
CN-116284080-A Dihydropyrimidine derivative containing boric acid and boric acid pinacol ester group, and preparation method and application thereof 山东大学 2023-06-23 CN disclosed
CN-112920208-B Boric acid-containing indole aryl sulfone derivative and preparation method and application thereof 山东大学 2022-11-08 CN disclosed
CN-108700686-A Colored resin composition for color filter, pigment dispersion liquid, color filter, and display device DNP精细化工股份有限公司 2018-10-23 CN disclosed
CN-107003448-A Color material dispersion liquid, photosensitive colored resin composition, color filter, liquid crystal display device, and organic light-emitting display device DNP精细化工股份有限公司 2017-08-01 CN disclosed
US-20090069320-A1 Substituted 4-Amino-Quinazoline Compounds with Metabotropic Glutamate Receptor Regulating Activity and Uses Thereof GRUENENTHAL GMBH (DE) 2009-03-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069320-A1 Substituted 4-Amino-Quinazoline Compounds with Metabotropic Glutamate Receptor Regulating Activity and Uses Thereof GRM1, GRIN1, GRM2 TSHR 991/4885TRPA1 1375/4885ALDH1A1 2269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.